Headlands Technologies LLC Purchases New Shares in CRISPR Therapeutics AG (NASDAQ:CRSP)

Headlands Technologies LLC purchased a new stake in CRISPR Therapeutics AG (NASDAQ:CRSP) during the second quarter, Holdings Channel reports. The institutional investor purchased 3,440 shares of the company’s stock, valued at approximately $186,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Capital International Investors boosted its stake in CRISPR Therapeutics by 27.8% during the 1st quarter. Capital International Investors now owns 7,837,074 shares of the company’s stock worth $534,175,000 after purchasing an additional 1,702,624 shares during the last quarter. Vanguard Group Inc. boosted its stake in CRISPR Therapeutics by 2.9% during the 1st quarter. Vanguard Group Inc. now owns 1,636,799 shares of the company’s stock worth $111,564,000 after purchasing an additional 46,148 shares during the last quarter. SR One Capital Management LP acquired a new stake in CRISPR Therapeutics during the 1st quarter worth $71,496,000. Charles Schwab Investment Management Inc. boosted its stake in CRISPR Therapeutics by 2.4% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 653,023 shares of the company’s stock worth $40,879,000 after purchasing an additional 15,085 shares during the last quarter. Finally, Norges Bank acquired a new stake in CRISPR Therapeutics during the 4th quarter worth $38,661,000. Institutional investors and hedge funds own 69.20% of the company’s stock.

CRISPR Therapeutics Trading Up 6.6 %

Shares of CRSP opened at $48.94 on Friday. The firm has a market cap of $4.16 billion, a P/E ratio of -17.99 and a beta of 1.68. CRISPR Therapeutics AG has a 12-month low of $37.55 and a 12-month high of $91.10. The company’s 50-day moving average price is $51.12 and its 200 day moving average price is $58.43.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings results on Monday, August 5th. The company reported ($1.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.43) by ($0.06). The business had revenue of $0.52 million for the quarter, compared to the consensus estimate of $12.31 million. CRISPR Therapeutics’s revenue for the quarter was down 99.3% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.98) EPS. Equities research analysts forecast that CRISPR Therapeutics AG will post -5.6 earnings per share for the current year.

Insiders Place Their Bets

In other CRISPR Therapeutics news, COO Julianne Bruno sold 3,366 shares of the business’s stock in a transaction dated Friday, June 21st. The shares were sold at an average price of $56.09, for a total transaction of $188,798.94. Following the sale, the chief operating officer now directly owns 6,745 shares in the company, valued at $378,327.05. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 4.10% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have issued reports on CRSP. StockNews.com raised shares of CRISPR Therapeutics to a “sell” rating in a research note on Friday, August 16th. Truist Financial lowered their target price on shares of CRISPR Therapeutics from $120.00 to $100.00 and set a “buy” rating on the stock in a research note on Monday, August 12th. Guggenheim reissued a “neutral” rating on shares of CRISPR Therapeutics in a research report on Friday, June 28th. Piper Sandler reissued an “overweight” rating and set a $105.00 price target on shares of CRISPR Therapeutics in a research report on Monday, June 17th. Finally, Cantor Fitzgerald reissued a “neutral” rating on shares of CRISPR Therapeutics in a research report on Thursday, August 8th. Three equities research analysts have rated the stock with a sell rating, eight have given a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat.com, CRISPR Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $75.63.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.